These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2880981)

  • 1. Experimental pharmacological study of moroxybrate, a hypolipidaemic, antithrombotic, antiatheromatous agent.
    Moreau P; Jacotot B; Tillement JP
    J Pharm Pharmacol; 1987 Jan; 39(1):35-8. PubMed ID: 2880981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A clofibric acid derivative with hypolipemic and platelet antiaggregant action].
    Dănilă G; Nechifor M; Filip M; Păduraru I; Ifrim C; Grădinariu D; Papa V; Manolescu A; Bădescu A
    Rev Med Chir Soc Med Nat Iasi; 1988; 92(1):127-32. PubMed ID: 3393745
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of Ciprofibrate on platelet aggregation and fibrinolysis in patients with hypercholesterolaemia.
    Simpson IA; Lorimer AR; Walker ID; Davidson JF
    Thromb Haemost; 1985 Aug; 54(2):442-4. PubMed ID: 4082082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Experimental research on the action of a derivative from a p-chloropenoxyisobutyric acid series on lipid parameters].
    Filip M; Hriscu A; Păduraru I; Rusu M
    Rev Med Chir Soc Med Nat Iasi; 1986; 90(1):156-60. PubMed ID: 3764166
    [No Abstract]   [Full Text] [Related]  

  • 5. Platelet antiaggregant activity of plafibride ex vivo in rat, dog and rabbit.
    Bruseghini L; Vilageliu J; Freixes J
    Arzneimittelforschung; 1981; 31(10a):1790-5. PubMed ID: 6797443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of amino acid derivative of clofibric acid (WKLB-5), and theophylline monoester of nicotinic acid (ME1) on the development of experimental atherosclerosis in rabbits.
    Wójcicki J; Jaworska M; Samochowiec L; Hinek A
    Pol J Pharmacol Pharm; 1986; 38(1):77-84. PubMed ID: 3509959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of the effects of plafibride and lysine acetyl salicylate on the production of PGI2].
    Lasierra J; Díez MM; Fernández A; Viladés E; Gil M; Velázquez E
    Sangre (Barc); 1983; 28(6):687-95. PubMed ID: 6424250
    [No Abstract]   [Full Text] [Related]  

  • 8. Metabolic effects of a new hypolipidemic agent, ciprofibrate.
    Arnold A; McAuliff MP; Beyler AL
    J Pharm Sci; 1979 Dec; 68(12):1557-8. PubMed ID: 529054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissociation of hypolipidemic and antiplatelet actions from adverse myotonic effects of clofibric acid related enantiomers.
    Feller DR; Kamanna VS; Newman HA; Romstedt KJ; Witiak DT; Bettoni G; Bryant SH; Conte-Camerino D; Loiodice F; Tortorella V
    J Med Chem; 1987 Aug; 30(8):1265-7. PubMed ID: 2441050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimulation of anti-aggregatory activity from rat aorta by hypolipidemic drugs.
    Weithmann KU; Granzer E
    Artery; 1980; 8(5):475-81. PubMed ID: 7011266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of bezafibrate and clofibrate on microsomal ACAT and lysosomal cholesterol ester hydrolase activity in the cholesterol-fed rabbit aorta.
    Hudson K; Day AJ
    Atherosclerosis; 1982 Oct; 45(1):109-13. PubMed ID: 7159486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypolipemic profile of plafibride in a model of experimental atherosclerosis.
    Badimón JJ; Padró T; Cánovas M; Vidal M; Villaverde CA
    Methods Find Exp Clin Pharmacol; 1983 Nov; 5(9):613-7. PubMed ID: 6668971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The action of a fibric acid derivative on lipid metabolism].
    Filip M; Păduraru I; Nechifor M; Dănilă GH; Popovici I; Filip FM; Poşircă F
    Rev Med Chir Soc Med Nat Iasi; 1989; 93(3):573-6. PubMed ID: 2636755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the hypolipidemic drug bezafibrate on the hepatic mixed function oxidase system of the rat: heterogeneity monooxygenase responses.
    Facino RM; Carini M
    Pharmacol Res Commun; 1981 Oct; 13(9):861-71. PubMed ID: 7335763
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical trials of plafibride in geriatric patients.
    Demichelis Genesio MA; Bracons R; Vicens B; Zapatero J; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1852-5. PubMed ID: 7198465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hypolipemic effect of amino acid derivatives of clofibric acid].
    Wójcicki J; Samochowiec L; Gawrońska-Szklarz B; Kwapiszewski W; Borkowski L
    Acta Pol Pharm; 1985; 42(3):305-8. PubMed ID: 4096253
    [No Abstract]   [Full Text] [Related]  

  • 17. [Research regarding the action of a derivative of the clofibric acid series on lipid metabolism].
    Filip M; Păduraru I; Hriscu A; Neacşu R; Dănilă G; Filip F
    Rev Med Chir Soc Med Nat Iasi; 1987; 91(2):341-5. PubMed ID: 3685700
    [No Abstract]   [Full Text] [Related]  

  • 18. Synthesis and pharmacological evaluation of N'-morpholinomethylurea derivatives with platelet antiaggregant activity.
    Ribalta JM; Artús JJ; Salvador L; Roma E; Vilageliu J; Freixes J; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1782-6. PubMed ID: 6797442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of clofibric acid and bezafibrate administration on activities of alkaline phosphatase and other enzymes in livers of rats.
    Walli AK; Seidel D
    Res Exp Med (Berl); 1981; 179(2):153-61. PubMed ID: 7280363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of ciprofibrate on gastric secretion in the rat.
    Eason CT; Pattison A; Howells DD; Bonner FW
    J Pharm Pharmacol; 1988 Jul; 40(7):512-3. PubMed ID: 2904995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.